Development of a potent respiratory syncytial virus-specific monoclonal antibody for the prevention of serious lower respiratory tract disease in infants.
Young
J
J
Research and Development, Medimmune Inc., Gaithersburg, MD 20878, USA. YoungJ@MedImmune.Com
D000818:Animals; D000911:Antibodies, Monoclonal / Q000008:administration & dosage*; D061067:Antibodies, Monoclonal, Humanized; D000998:Antiviral Agents / Q000008:administration & dosage*; D006801:Humans; D006825:Hybridomas; D007223:Infant; D007231:Infant, Newborn; D007235:Infant, Premature, Diseases / Q000517:prevention & control*; D051379:Mice; D008807:Mice, Inbred BALB C; D000069455:Palivizumab; D018357:Respiratory Syncytial Virus Infections / Q000517:prevention & control*; D018113:Respiratory Syncytial Virus, Human / Q000276:immunology*; D013678:Technology, Pharmaceutical; D014614:Vaccines, Synthetic / Q000008:administration & dosage*
D000911:Antibodies, Monoclonal; D061067:Antibodies, Monoclonal, Humanized; D000998:Antiviral Agents; D014614:Vaccines, Synthetic; D000069455:Palivizumab